Welcome to the Porton Newsroom
Porton Shared Complex Bioconjugate Development Strategies at the 17th World ADC San Diego
As a conference partner, Porton contributed a scientific presentation and poster addressing the technical challenges of developing ADCs and emerging bioconjugates.
Simplifying Synthesis with Radical Cross-Coupling: Prof. Phil S. Baran of Scripps Research Lectures at Porton
The event was hosted by Dr. Yongli Zhong, CSO, and attended by Mr. Oliver Ju, Chairman and CEO; Mr. Yunxing Yin, VP and Head of the Small Molecule Platform, and more than 200 R&D and technical staff.
Porton Achieves Third-Party Verification for Its First Commercial Product LCA and PCF Study
Conducted in accordance with ISO 14040:2006 and ISO 14044:2006 (Life Cycle Assessment) and ISO 14067:2018 (Product Carbon Footprint) standards, the study employs a cradle-to-gate system boundary, marking the formal extension of Porton's ESG management from the organizational level to the product level.
Porton Successfully Concludes CPHI Milan 2026, Showcasing Integrated CDMO Capabilities and Connecting for Global Pharma Innovation
Porton Pharma Solutions showcased its capabilities at the event, engaging in multiple face-to-face meetings with pharmaceutical and biotech companies and industry partners from Europe and around the world at Booth 10K6, discussing drug development trends, supply chain challenges, and diverse CDMO collaboration opportunities.
Porton Newsletter - September, 2026 Recap
Porton Recognized by LyncBio Therapeutics for ADC Payload-Linker CMC Capabilities
Porton Chongqing Liangjiang Drug Product Manufacturing Site Earns Recertification of ISO 14001 & ISO 45001
PMO Therapeutics: Technical Review and Manufacturing Platform Capabilities
Porton Recognized by LyncBio Therapeutics for ADC Payload-Linker CMC Capabilities
Porton, as the project's CDMO partner, completed process development and manufactured non-GMP toxicology batches and GMP clinical trial materials for LYNC-101's payload-linker.
Porton Chongqing Liangjiang Drug Product Manufacturing Site Earns Recertification of ISO 14001 & ISO 45001
This successful recertification highlights the standardized operation of the site's management systems, the rigor of its on-site management, and the robustness of its risk control mechanisms, further validating the continued effectiveness of the dual systems.
Porton to Showcase End-to-End CDMO Expertise at CPHI Milan 2026
CPHI creates connections and inspires partnerships across the global pharma community, championing innovation at the heart of pharma through in-person and online events that grant access to endless opportunities.
Porton Newsletter - August 2026 Recap
Porton Reports H1 2026 Results
Porton Appoints Dr. Yongli Zhong as Chief Scientific Officer
Porton Appoints Yunxing Yin as Corporate Vice President to Strengthen Small-Molecule R&D Leadership
